These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7942168)

  • 1. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta.
    Brenner RE; Vetter U; Bollen AM; Mörike M; Eyre DR
    J Bone Miner Res; 1994 Jul; 9(7):993-7. PubMed ID: 7942168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta.
    Minisola S; Rosso R; Romagnoli E
    J Bone Miner Res; 1995 Feb; 10(2):335-9. PubMed ID: 7754815
    [No Abstract]   [Full Text] [Related]  

  • 3. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency.
    Kamel S; Brazier M; Rogez JC; Vincent O; Maamer M; Desmet G; Sebert JL
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3717-21. PubMed ID: 8855828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides.
    Bollen AM; Eyre DR
    Bone; 1994; 15(1):31-4. PubMed ID: 8024848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian variation in urinary excretion of bone collagen cross-links.
    Bollen AM; Martin MD; Leroux BG; Eyre DR
    J Bone Miner Res; 1995 Dec; 10(12):1885-90. PubMed ID: 8619368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.
    Hanson DA; Weis MA; Bollen AM; Maslan SL; Singer FR; Eyre DR
    J Bone Miner Res; 1992 Nov; 7(11):1251-8. PubMed ID: 1466251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
    Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
    Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary cross-linked N-telopeptides of type I collagen and bone metabolic diseases.
    Xue Y; Jia W; Zhang H; Dong J; Clemens JD; Tian X
    Chin Med J (Engl); 1999 Feb; 112(2):149-52. PubMed ID: 11593583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary excretion of cross-linked N-telopeptides of type 1 collagen to assess bone resorption in infants from birth to 1 year of age.
    Lapillonne A; Travers R; DiMaio M; Salle BL; Glorieux FH
    Pediatrics; 2002 Jul; 110(1 Pt 1):105-9. PubMed ID: 12093954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary Cross-linked N-terminal Telopeptide of Type I Collagen Levels of Infants with Osteogenesis Imperfecta and Healthy Infants.
    Yamashita M; Hasegawa K; Higuchi Y; Miyai T; Okada A; Tanaka H; Tsukahara H
    Acta Med Okayama; 2016 Dec; 70(6):435-439. PubMed ID: 28003667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cross-linked N-telopeptides of type I collagen(NTX)].
    Saito S; Nakatsuka K
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():358-62. PubMed ID: 15035152
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone turnover markers in patients with osteogenesis imperfecta.
    Braga V; Gatti D; Rossini M; Colapietro F; Battaglia E; Viapiana O; Adami S
    Bone; 2004 Jun; 34(6):1013-6. PubMed ID: 15193547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Type I collagen crosslinked C-telopeptides].
    Hoshino H; Kushida K
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():365-8. PubMed ID: 15035153
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary markers of type I collagen degradation in the dog.
    Allen MJ; Allen LC; Hoffmann WE; Richardson DC; Breur GJ
    Res Vet Sci; 2000 Oct; 69(2):123-7. PubMed ID: 11020362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.
    Sakkers R; Kok D; Engelbert R; van Dongen A; Jansen M; Pruijs H; Verbout A; Schweitzer D; Uiterwaal C
    Lancet; 2004 May; 363(9419):1427-31. PubMed ID: 15121405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
    Garnero P; Schott AM; Prockop D; Chevrel G
    Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an immunoassay method for the determination of urinary collagen crosslink excretion.
    Hata K; Miura M
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():374-5. PubMed ID: 7979105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.